Source:Radiotherapy and Oncology
Author(s): Peter G. Hawkins, Philip S. Boonstra, Stephen T. Hobson, Jason W.D. Hearn, James A. Hayman, Randall K. Ten Haken, Martha M. Matuszak, Paul Stanton, Gregory P. Kalemkerian, Nithya Ramnath, Theodore S. Lawrence, Matthew J. Schipper, Feng-Ming (Spring) Kong, Shruti Jolly
Background and purposeCurrent methods to estimate risk of radiation-induced lung toxicity (RILT) rely on dosimetric parameters. We aimed to improve prognostication by incorporating clinical and cytokine data, and to investigate how these factors may interact with the effect of mean lung dose (MLD) on RILT.Materials and methodsData from 125 patients treated from 2004 to 2013 with definitive radiotherapy for stages I-III NSCLC on four prospective clinical trials were analyzed. Plasma levels of 30 cytokines were measured pretreatment, and at 2 and 4weeks midtreatment. Penalized logistic regression models based on combinations of MLD, clinical factors, and cytokine levels were developed. Cross-validated estimates of log-likelihood and area under the receiver operating characteristic curve (AUC) were used to assess accuracy.ResultsIn prognosticating grade 3 or greater RILT by MLD alone, cross-validated log-likelihood and AUC were −28.2 and 0.637, respectively. Incorporating clinical features and baseline cytokine levels increased log-likelihood to −27.6 and AUC to 0.669. Midtreatment cytokine data did not further increase log-likelihood or AUC. Of the 30 cytokines measured, higher levels of 13 decreased the effect of MLD on RILT, corresponding to a lower odds ratio for RILT per Gy MLD, while higher levels of 4 increased the association.ConclusionsAlthough the added prognostic benefit from cytokine data in our model was modest, understanding how clinical and biologic factors interact with the MLD-RILT relationship represents a novel framework for understanding and investigating the multiple factors contributing to radiation-induced toxicity.
http://ift.tt/2yywSGH
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου